• ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blogs
    • Case Studies
    • Podcasts
    • Webinars
    • White Papers
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  • ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blogs
    • Case Studies
    • Podcasts
    • Webinars
    • White Papers
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  1. Home
  2. Services
  3. Clinical Pharmacology Modeling Simulation
  4. DMPK and Translational Discovery and Development
    • Drug-Drug Interaction (DDI) Strategy
    • Nonclinical PK, TK, and PD Analyses
    • Nonclinical Strategy, Study Design, and Analysis

DMPK and Translational Discovery and Development

  • Clinical Pharmacology Modeling Simulation
  • Clinical Pharmacology Integrated Drug Development
    • Clinical Study Strategy and Design
    • Development and Regulatory Strategy
    • Regulatory Representation, Writing, and Submissions
    • Scientific/Technical Writing, Manuscripts, and Communication
  • Model Informed Dose & Drug Development (MIDD)
    • Dose Translation, Rationale, and Justification
    • Bridging and Extrapolation Approaches
    • Modeling and Simulation
  • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
    • Data Management, Programming, and CDISC Dataset Creation
    • Noncompartmental PK Analysis (NCA)
    • Population Pharmacokinetics (popPK)
  • DMPK and Translational Discovery and Development
    • Drug-Drug Interaction (DDI) Strategy
    • Nonclinical PK, TK, and PD Analyses
    • Nonclinical Strategy, Study Design, and Analysis

Drug metabolism and pharmacokinetics (DMPK) is an essential part of drug discovery and development. A central role of DMPK is to help optimize new molecular entities (NME) in Discovery, including small molecules and biologics, by assessing their absorption, distribution, metabolism, excretion (ADME), and pharmacokinetic (PK) properties. Similar to DMPK studies, nonclinical pharmacodynamic (PD) studies use relevant in vitro and in vivo models of disease to provide valuable information about the potential efficacy profile of candidate therapeutics.

Understanding these properties helps drug developers identify key features and potential risks such as drug-drug interactions (DDIs), off-target effects, or immunogenicity for optimization and mitigation, thereby ensuring that the best possible candidates are advanced into clinical development. Although in-depth nonclinical DMPK and PD evaluation can improve the probability of success for new drug candidates, new therapies in early clinical trials routinely fail due to sub-optimal ADME, PK, and PD properties. This emphasizes the central importance of a robust nonclinical study strategy within the Discovery phase, not only in selecting the best candidates for clinical development but also because it generates data that are critical in predicting likely outcomes in humans.

There has been tremendous progress in technology platforms and biosimulation techniques that enable the application of model-informed drug discovery and development approaches, such as physiologically based PK (PBPK), quantitative systems pharmacology (QSP), and quantitative systems toxicology (QST) modeling. The net result is that ADME, PK, and PD data are effectively translated into meaningful and interpretable clinical outcomes that provide a greater quantitative understanding of candidate attributes to enable more informed, timely, and effective decision-making.

DMPK and Translational Discovery and Development Services

Allucent’s scientists have drug discovery experience and expertise to help plan and execute your program’s DMPK screening funnels, studies, clinical translation, and development strategy. Learn more about how Allucent can help support your early drug discovery and development programs with our DMPK and translational discovery services including:

  • Drug-Drug Interaction (DDI) Strategy
  • Nonclinical PK, TK, and PD Analyses
  • Nonclinical Strategy, Study Design, and Analysis
  • Physiologically Based Pharmacokinetics (PBPK) and Quantitative Systems Pharmacology (QSP)

Contact Us

Let us partner with your team on bringing new therapies to light. Get in touch to get started.

CONTACT US

  • Services
    • Clinical Trial Operations
    • Regulatory and Drug Development Consulting
    • Government and Public Health Services
    • Biometrics
    • Clinical Pharmacology Modeling Simulation
  • Therapeutic Expertise
    • Oncology and Hematology
    • Rare Diseases and Orphan Drugs
    • Infectious Disease and Vaccine
    • Cell and Gene Therapy
    • Central Nervous System
    • Autoimmune and Inflammation
    • Allergy and Asthma
  • Company
    • About Us
    • News
    • Events
  • Privacy Policy
  • English
  • Francais

© 2023 Allucent. All rights

North American Headquarters
2000 Centregreen Way
Suite 300
Cary, North Carolina 27513
+1 919-361-2286

United Kingdom Headquarters
1st Floor, One Station Square,
Bracknell, Berkshire
RG12 1QB United Kingdom
T: +44 (0) 1344 891121
F: +44 (0) 1344 890335

European Headquarters
Stationsplein Noord-Oost 438
1117 CL Schiphol
The Netherlands
+31 20-4350-580